Apolipoprotein A-I (ApoA-I) (ApoA-I)

Apolipoprotein A-I (ApoA-I) is the primary protein component of high-density lipoprotein (HDL) particles and plays a critical role in lipid metabolism (UniProt: P02647). Its main biological function is to facilitate reverse cholesterol transport, a process where excess cholesterol is removed from peripheral tissues, including arterial walls, and transported to the liver for excretion (StatPearls: Physiology, Cholesterol). Beyond lipid transport, ApoA-I exhibits potent anti-inflammatory, antioxidant, and anti-thrombotic properties that contribute to vascular health (PubMed: PMID 29030331). In the context of cardiovascular disease, low levels of ApoA-I are strongly associated with an increased risk of atherosclerosis and myocardial infarction (PubMed: PMID 31513851). Therapeutic strategies targeting this pathway include the infusion of reconstituted HDL (rHDL) mimetics like CSL112 to stabilize plaques and small molecules like apabetalone designed to increase endogenous ApoA-I expression (ClinicalTrials.gov: NCT03473223, NCT02584777). While these interventions effectively enhance cholesterol efflux capacity, recent large-scale clinical trials have faced challenges in demonstrating significant reductions in acute cardiovascular events (PubMed: PMID 38581154).

Other names

ApoA1Apolipoprotein A1HDL-associated protein-lipid complexApolipoprotein A-I pathwayReconstituted high-density lipoprotein (rHDL)

The Apolipoprotein A-I pathway is targeted through two primary mechanisms: the direct intravenous infusion of reconstituted HDL (rHDL) complexes, which consist of ApoA-I and phospholipids, to immediately enhance cholesterol efflux from atherosclerotic plaques (PubMed: PMID 38581154); and the pharmacological induction of endogenous ApoA-I synthesis using small molecules like BET inhibitors, which promote the transcription of the APOA1 gene in the liver (PubMed: PMID 31513851).